about
[Occurrence of disseminated intravascular coagulation in purulent meningitis and influence on mortality in 118 patients].The prevalence and co-occurrence of hematological complications at the time of diagnosis of chronic hepatitis C in Poland: a cross-sectional study.Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C.High-throughput matrix-assisted laser desorption ionization-time of flight mass spectrometry as an alternative approach to monitoring drug resistance of hepatitis B virus.An initial assessment of correlations between host- and virus-related factors affecting analogues antiviral therapy in HBV chronically infected patientsThe extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people.Associations between HIV-RNA-based indicators and virological and clinical outcomes.Hepatotropic viruses seen by clinicians.Coagulation, coma, and outcome in bacterial meningitis--an observational study of 38 adult cases.Does hepatitis B virus or hepatitis C virus infection influence CD4 count in HIV-positive individuals?Dermoscopic observations in disseminated cryptococcosis with cutaneous involvement.[Sepsis in HIV-positive patients--own observation].Opportunistic infections and other AIDS-defining illnesses in Poland in 2000-2002.[Opportunistic infections in HIV-positive patients hospitalized in the Clinic of Infectious Diseases AMG].Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort[Immune mechanisms in HIV infection and their role in antiretroviral therapy]Role of coagulation in predicting the outcome of bacterial meningitis[HIV infected child in otolaryngological practice][Assessment of energy intake in HIV--positive adults]The role of dermoscopy in the diagnosis of deep mycoses and systemic mycoses with cutaneous involvement: Comment on 'Dermoscopy in disseminated sporotrichosis'Streptococcus suis Meningitis: Epidemiology, Clinical Presentation and TreatmentCOVID-19 - toward a comprehensive understanding of the disease
P50
Q33372597-6A586FE0-D766-4E0D-8274-1E44D68F47EFQ33432848-A8386B18-BE0A-4FF2-88BD-DA5391D1AB95Q33600034-AD545D57-87D8-42D0-8218-B82A635307E0Q34997985-606C9752-D072-4168-895E-8D061D436C0BQ35102963-0E7A5EA0-D442-45E1-9CAD-E78FFFA623D9Q39455597-48E48BCB-0625-4E5D-BA6F-71FF146DE7ECQ40686293-94C27DEF-E895-4613-B4BA-B02DE1471632Q41337591-64E5A7C2-B119-47EF-9F90-9C45E381658BQ44108944-F9EBC0BF-8342-4221-B5F0-A70D2D8F414FQ45764959-BAE89A5B-02C9-4AFA-AEA9-2F136EF3BB62Q49970772-43028A76-8D90-422B-A760-4B8D18FCA858Q52281013-191551B5-A8E1-4840-9472-36ADB8288AAEQ53768335-DF95EFE1-8CCC-44D8-975C-611D088A1EC5Q53831840-8DB8AD99-7777-4FAC-B329-CDEA52DED934Q57795365-5F6B8589-8CDD-4A77-A8AC-48DC64B7E08AQ73792370-D4F8BBDD-A48B-4837-BF51-95A25959284BQ80416115-EB3C87B9-EFEE-4CE1-B3E9-CE3E4C3D5352Q81662541-9D60EA28-3C37-4244-8775-DF07C99D2863Q84629807-0DD881DB-0C9A-484F-A5F2-EB6F50CFBC92Q89313238-E7241ECB-0290-4F7F-BEE3-AB644543F4C2Q92263448-454B0C55-E59F-42D8-AB7A-F3992100801DQ94602677-2CCA44D6-D1EE-41B7-9F30-FE1650659AF8
P50
description
researcher ORCID ID = 0000-0003-2793-3671
@en
wetenschapper
@nl
name
T Smiatacz
@ast
T Smiatacz
@en
T Smiatacz
@es
T Smiatacz
@nl
type
label
T Smiatacz
@ast
T Smiatacz
@en
T Smiatacz
@es
T Smiatacz
@nl
prefLabel
T Smiatacz
@ast
T Smiatacz
@en
T Smiatacz
@es
T Smiatacz
@nl
P1153
6602362044
P31
P496
0000-0003-2793-3671